The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated ...

Should the Tryvio deal come through in the coming days, this is likely to add another 30 million Swiss francs ($33.4 million) to Idorsia’s bank balance.

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...